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20 ABSTRACT
21 Background: Diabetic maculopathy is a form of diabetic retinopathy. The visual acuity of one 
22 third of patients with diabetic maculopathy will be affected. The purpose of this study was to 
23 identify genetic contributors of diabetic maculopathy with decreased visual acuity based on a 
24 genome-wide association approach using a well-defined Scottish diabetic cohort. 
25 Methods: We used linked e-health records of diabetic patients to define our cases and 
26 controls. The cases in this study were defined as type 2 diabetic patients who had ever been 
27 recorded in the linked e-health records as having maculopathy (observable or referable) in at 
28 least one eye and whose visual acuity of the eye was recorded to have decreased between the 
29 first and the last visual acuity record of that eye in the longitudinal e-health records. The 
30 controls were defined as a type 2 diabetic individual who had never been diagnosed with 
31 maculopathy or retinopathy in the link d e-health records. Anyone who had laser 
32 photocoagulation treatment was also excluded from the controls. A standard genome-wide 
33 association approach was applied. 
34 Results: Overall, we identified 469 cases and 1,374 controls within the Genetics of Diabetes 
35 Audit and Research in Tayside Scotland (GoDARTS) dataset. We found that the P value of 
36 rs9966620 in the TTC39C gene was 4.13x10-8, which reached genome-wide significance. 
37 Conclusions: We suggest that the TTC39C gene is associated with diabetic maculopathy with 
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45 Maculopathy is defined as any pathological condition affecting the macula, a highly sensitive 
46 region located centrally on the retina which is responsible for sharp, clear, and accurate colour 
47 vision (1). It is commonly associated with old age, eye surgery/trauma and diabetes mellitus (1). 
48 Maculopathy commonly causes impaired vison but in severe cases can lead to blindness (2). 
49 According to a report by the World Health Organization in 2014, maculopathy was responsible 
50 for 3.1% of all visual impairment and 6.6% of all blindness in 2010 (2,3). Between 1990 – 2010, 
51 there was an 81% increase in the number of visually impaired people and a 36% increase in 
52 numbers of blind people due to maculopathy(2). Maculopathy and its subsequent visual 
53 disturbances are linked to many adverse health issues. One such example is falls, which 
54 (especially in geriatric patients) can result in fractures, subsequent reduction in quality of life, 
55 and an increased number of years spent with disability (4). The economic impact of 
56 maculopathy is enormous, with an estimated cost of over £100M in 2010 in England alone, 
57 incorporating aspects such as screening, management and home care (5).
58 Diabetic maculopathy (DM) is a type of diabetic retinopathy and it is a major eye complication 
59 and visual impairment amongst people with diabetes (2). According to the latest diabetic 
60 retinopathy guidelines by The Royal College of Ophthalmologists in the UK, DM can be 
61 classified as either focal oedema, diffuse oedema, ischemic, or mixed (6). An epidemiological 
62 study of DM in Germany showed a prevalence rate of 15% in type 1 and 23% in type 2 diabetic 
63 patients (7). Environmental risk factors of DM include longer duration of diabetes, high glycated 
64 haemoglobin (HbA1C) levels, prior high-risk proliferative diabetic retinopathy, presence of 
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65 diabetic neuropathy, hypertension, anaemia, elevated serum lipid (triglycerides and cholesterol) 
66 levels and raised creatinine levels (7–9).
67 The genetic mechanism of DM is poorly understood and only limited numbers of genetic studies 
68 have been performed, particularly on diabetic macular oedema, a subtype of DM. One of these 
69 studies suggested that three polymorphisms in the nitric oxide synthase 3 (NOS3) gene were 
70 associated with an increased risk of developing diabetic macular oedema (10). The C-634G 
71 polymorphism in the vascular endothelial growth factor A (VEGFA) gene has also been 
72 demonstrated to be associated with development of diabetic macular oedema and diabetic 
73 retinopathy, in addition to correlating with macular retina thickness in type 2 diabetics (11). More 
74 recently, genetic variations in MicroRNA-146a and the vascular endothelial growth factor C 
75 (VEGFC) gene were found to be significantly associated with diabetic macular oedema in 
76 patients with type 2 diabetes (12,13). Whilst there have been a few genome-wide association 
77 studies (GWAS) performed on diabetic retinopathy across various ethnic groups, no GWAS 
78 have yet been performed specifically on DM (14–17). Graham PS et al. has performed a GWAS 
79 on diabetic macular oedema although no GWAS significance was generated. (18)
80 Given the fact that people are living longer with diabetes and the increasing prevalence of 
81 diabetic eye complications including maculopathy, it is necessary to understand the genetic 
82 mechanisms of DM as we seek new ways to relieve the burden of morbidity that DM creates 
83 worldwide. Therefore, this study seeks to identify genetic variants for DM using a GWAS 
84 approach in a well-defined diabetes cohort within Scotland.
85
86 MATERIALS AND METHODS
87 Participants 
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88 To identify genetic risk factors for diabetes and its complications, the Genetics of Diabetes Audit 
89 and Research in Tayside Scotland (GoDARTS) project was established in 2005. All participants 
90 (including diabetic and non-diabetic individuals, mainly Scottish) completed a lifestyle 
91 questionnaire, a baseline clinical examination, and provided their biological samples (blood 
92 and/or urine). The participants also gave broad consent to allow their health information and 
93 biological samples to be used for future scientific research purposes. In addition, the 
94 participants gave permission to have their personal information linked to the National Health 
95 Service (NHS) medical records anonymously. This information included their personal health 
96 status, their general practice clinic visits, outpatient appointments, prescribing history and 
97 hospital admissions. Furthermore, their personal information was also anonymously linked with 
98 the Scottish Care Information-Diabetes Collaboration (SCI-DC) database, which is another 
99 electronic health record system designed to track local diabetic patients and help health 
100 professionals to provide better health care in Scotland. Further information about the GoDARTS 
101 project is available in the public domain at https://godarts.org. This study has followed the 
102 principles of the Declaration of Helsinki. Ethics approval has been granted by Tayside 
103 Committee on Medical Research Ethics (REC reference 053/04). 
104 At the time of this study, the GoDARTS project had recruited 9,439 diabetic patients, 6,927 of 
105 which were already genotyped by DNA chips. All GoDARTS participants’ health information 
106 was anonymously linked with their NHS and SCI-DC medical records from June 1996 until June 
107 2011.
108 Definition of cases and controls
109 The cases in this study were defined as type 2 diabetic patients who had ever been recorded in 
110 the linked e-health records as having maculopathy (observable or referable) in at least one eye 
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111 and whose visual acuity of the eye was recorded to have decreased between the first and the 
112 last visual acuity record of that eye in the longitudinal e-health records. The controls were 
113 defined as a type 2 diabetic individual who had never been diagnosed with maculopathy or 
114 retinopathy in the linked e-health records. Anyone who had laser photocoagulation treatment 
115 was also excluded from the controls. A standard genome-wide association approach was 
116 applied. The definition of visual acuity is summarized in Supplementary Table S1. The 
117 diagnosis of DM and assessment of visual acuity was performed by ophthalmologists within the 
118 annual national retinal screening service offered to diabetic patients. The diagnostic criteria for 
119 diabetic retinopathy or DM are summarized in the Supplementary Table S2. 
120 Genotyping and quality control 
121 The GoDARTS project used two types of DNA chips to genotype its participants with diabetes. 
122 The SNP6.0 (Affymetrix, Santa Clara, CA, USA) chips were used on 3,673 subjects, and the 
123 OmniExpress (Illumina, Inc., San Diego, CA, USA) chips were used on 3,254 subjects. The 
124 standard genotyping quality-control protocols were established for the above studies (WTCCC2 
125 and SUMMIT) (19,20).  
126 Statistical analysis 
127 The imputation of non-directly genotyped single nucleotide polymorphisms (SNPs) was carried 
128 out using SHAPEIT and IMPUTE2 software, with reference files from the 1000 genome phase I 
129 datasets (21,22). The cut-off value (r2 < 0.3) recommended by IMPUTE2 was applied to remove 
130 poorly imputed SNPs.
131 Standard quality control steps were applied during data analysis, such as removal of individuals 
132 with more than 5% genotype data missing, SNPs with missing genotype of more than 5%, or 
133 SNPs with less than 1% minor allele frequency and SNPs that failed Hardy–Weinberg tests (P < 
Page 6 of 31
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134 0.000001). PLINK was used as the primary software for data analysis 
135 (https://www.cog-genomics.org/plink2) (23). SNPs on sex chromosomes and mitochondria 
136 were also excluded. Detection of population stratification and removal of population outliers 
137 were performed using the multidimensional scaling (MDS) analysis integrated in PLINK. To 
138 indicate the level of stratification, a lambda value was generated by MDS. Samples with pi-hat > 
139 0.125 were removed due to relatedness. P values were calculated by the logistic regression 
140 tests integrated in PLINK with covariates of age, sex, body mass index (BMI), cholesterol, 
141 triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and HbA1c (using the 
142 latest available health records). A P value of less than 5 x 10-8 was considered to be 
143 statistically significant.
144 This study also used many GWAS related software such as FUMA for generating Manhattan 
145 plots, LocusZoom for regional visualization, and FUMA for generating a corresponding Q-Q plot 
146 to evaluate differences between the cases and controls caused by potential confounders (e.g. 
147 different genotyping laboratories, different DNA extraction methods, etc.) (24,25). SPSS 22 
148 software (IBM Corp., Armonk, NY, USA) was used to compare means of all covariates (except 
149 sex) in cases and controls through the independent sample t-test. Sex difference was 
150 compared by chi-square test. The whole workflow is shown in Supplementary Figure S1. 
151
152 RESULTS
153 After excluding type 1 diabetic samples, population outliers, and related samples from 6,927 
154 diabetic patients with genetic information from Affymetrix and Illumina chips, we were left with a 
155 study population of 4,852 unrelated type 2 diabetes individuals for further analysis. Among 
156 these patients, we identified 1,240 samples with diabetic maculopathy. However, only 469 
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157 participants had a decreased visual acuity in the corresponding eye and were suitable for 
158 inclusion as cases. We also identified 1,374 patients as controls, after excluding patients who 
159 had diabetic retinopathy without DM, patients who had previous laser treatment, and patients 
160 who were already cases. Therefore, there were 469 cases (males=192, females=277) and 
161 1,374 controls (males=630, females=744) for the further association analysis. The prevalence 
162 of diabetic maculopathy with decreased visual acuity in our cohort was 25.4% 
163 [469/(469+1,374)]. The means of sex, age, BMI, cholesterol, triglycerides, HDL, LDL, HbA1c 
164 were compared between cases and controls. There were statistically significant differences in 
165 age, triglycerides, HDL and HbA1c between the cases and controls, but no statistically 
166 significant difference in sex, BMI, cholesterol and LDL (Table 1).
167 Affymetrix SNP6.0 chips contained 704,847 directly genotyped and quality-controlled SNPs and 
168 Illumina OmniExpress chips contained 601,394 directly genotyped and quality-controlled SNPs. 
169 Overall, 6,717,712 genotyped and imputed SNPs were available for association analysis after 
170 standard quality control steps of genotyping and imputation. There was no need to further 
171 adjust for population stratification since the lambda value was 1.00, indicating a homogeneous 
172 population. We then performed logistic regression tests integrated in PLINK adjusting for sex, 
173 age, BMI, cholesterol, triglycerides, HDL, LDL, HbA1c. We found that the SNP rs9966620 in the 
174 TTC39C gene, reached genome-wide significance (Table 2) with a P value of 4.13 x 10-8 and 
175 odds ratio of 1.95 (Confidence interval: 1.53-2.47, Figure 1). This finding was supported by the 
176 nearby SNPs (rs7243626 and rs7240470) which also showed encouraging P values (P= 
177 5.64x10-8 and 8.05x10-7, respectively). We calculated the LD among these SNPs using our 
178 dataset and these SNPs are highly correlated (R-square>0.8) (Supplementary Table S3). The 
179 regional plot around the top SNPs is shown in the Figure 2. The Q-Q plot of the association 
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180 results is shown in the Supplementary Figure S2. 
181 We have moderate power for this GWAS study. Calculated by CaTS, we have 80% power 
182 based on 469 cases and 1,374 controls, assuming a minor disease allele frequency of 0.25, a 
183 genotypic relative risk of 1.49, a prevalence of diabetic maculopathy with decreased visual 
184 acuity in the diabetic population of 25%, and significance level of 5 x 10-8 (26).
185 We also ran a GWAS on the phenotype of DM (regardless of visual acuity status, 1,240 cases) 
186 against the controls used in this study. The result did not show GWAS significance 
187 (Supplementary Table S4). 
188
189 DISCUSSION 
190 In Scotland, patients with diabetes are invited to attend a free annual retinal screening service. 
191 This screening service aims to identify diabetic eye complications at an early stage to prevent or 
192 delay subsequent visual loss. During the screening, if an eye falls within the diagnosis criteria of 
193 diabetic retinopathy or DM (Supplementary Table S2), then the relevant information will be 
194 recorded in the e-health linked records. The status of macula is then categorised and recorded 
195 as either: no maculopathy, observable maculopathy, or referable maculopathy. Diabetic 
196 retinopathy is further classified and recorded based on the Scottish diabetic retinopathy grading 
197 scheme (27). Because of the lack of more detailed classification info, it was not possible to 
198 phenotype the subtypes of DM (as outlined by The Royal College of Ophthalmologists 
199 guidelines) when using population e-health linked records such as GoDARTS (6), Decreased 
200 visual acuity is a well-recognised symptom associated with maculopathy. 22% of diabetic 
201 patients with decreased visual acuity have maculopathy, compared to 1% in diabetic patients 
202 with normal visual acuity (28). It is also estimated that 6 months after laser treatment, the visual 
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203 acuity of 34% of DM patients became worse, 22% became better, and 44% remained the same 
204 (29). These statistics were similar for DM patients who did not undergo laser treatment. In this 
205 study, 37.8% of patients (469/1240) who had DM also had a decreased visual acuity, which is 
206 only slightly higher than the above post-laser treatment statistics, however this could be 
207 attributed by the fact that we had a longer follow-up period. A national UK audit also found that 
208 a poor baseline visual acuity was associated with a poorer visual prognosis in DM patients (30). 
209 In this study, we defined the cases as DM with decreased visual acuity based on the hypothesis 
210 that these patients might share common genetic components. We tried to identify the genetic 
211 factors which contribute to decreased visual acuity among DM patients. Though this narrow 
212 definition will reduce case numbers and the study power, it allows us to generate a more 
213 homogeneous case population. A similar approach has been applied when we were defining 
214 diabetic neuropathic pain (the cases should not only have evidence of pain provided by 
215 prescription records, but also positive evidence of neuropathy provided by a medical test) (31). 
216 We also acknowledge that ‘decreased visual acuity’ in the cases was defined as any visual loss, 
217 including both major and minor visual loss, which may be an additional confounding factor. 
218 Because there is no literature which indicates if diabetic retinopathy and DM share the same 
219 genetic components, we also excluded individuals with diabetic retinopathy with and without 
220 DM from the controls to maintain a homogeneous population as we wanted to exclude genetic 
221 influence from diabetic retinopathy. The duration of diabetes is an important risk factor for many 
222 diabetic complications. However, the GoDARTS dataset does not include a high-quality record 
223 of this information. Hence, duration of diabetes therefore could not be adjusted for in our 
224 analysis. We also noticed that there were statistical differences of some covariates between 
225 cases and controls. For example, the mean HbA1c value was higher in cases than controls, 
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226 which suggest that the controls may have had better controlled diabetes and/or a longer 
227 duration of diabetes (32).
228 We have identified the SNP rs9966620, which has achieved GWAS significance (P=4.13 x 10-8, 
229 Odds ratio=1.95). This was supported by 2 nearby SNPs which showed encouraging P values. 
230 The 3 SNPs are located in the intronic areas with no clear functional roles. The SNP cluster was 
231 in the tetratricopeptide repeat domain 39C gene (TTC39C), which is a protein-coding gene 
232 located on the long arm of chromosome 18. The TTC39C gene is expressed in the eyes, and 
233 encodes a protein named as TTC39C (33). However, the physiological functions of both the 
234 gene and the protein are not known. The protein contains a relatively well-characterized 
235 structural motif called the tetratricopeptide repeat (TPR). The TPR is known to be involved in 
236 cell cycle regulation, mediating protein-protein interactions, assisting in protein folding and 
237 translocation, assembly of multi-protein complexes. The TPR structure also shows flexibility in 
238 the mediation of biological activities (34,35). In particular, it has been proposed that this 
239 structure plays a role in anaphase: the stage of mitosis when replicated chromosomes are split 
240 and the daughter chromatids are moved to opposite poles of the cell (36). Anaphase has been 
241 suggested to play an essential role in regulating cell fate of the vertebrate retina (37). Some 
242 studies have suggested that central macular thickness, a highly heritable trait with no specific 
243 gene identified, is associated with visual acuity (38,39). However, this parameter was not 
244 recorded our e-health linked records and so it is still unknown if the TTC39C gene is linked with 
245 central macular thickness. It has been suggested that the TTC39C protein interacts with the 
246 protein from the heat shock protein family B (small) member 1 (HSPB1) gene (40). HSPB1 is 
247 reported to be upregulated in the rat retina upon optic nerve injury (41). The TTC39C protein 
248 has 2 paralogs: TTC39A and TTC39B, although their functions are not clear. Next to TTC39C 
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249 are the laminin subunit alpha 3 gene (LAMA3) and the calcium binding tyrosine phosphorylation 
250 regulated gene (CABYR). Of note, the protein of LAMA3 is laminin subunit alpha-3 and laminins 
251 are essential for formation and function of the basement membrane and have additional 
252 functions in regulating cell migration and mechanical signal transduction, which suggests it is a 
253 possible candidate gene for diabetic maculopathy (42). 
254 We also investigated the top SNPs suggested by other candidate gene studies for diabetic 
255 macular oedema. However, none reached statistically significant P-values: rs2070744 
256 (P=0.286, NOS3), rs429358 (P=0.59, APOE), rs7412 (P= 0.35, APOE), rs2010963 (P=0.30, 
257 VEGFA), rs17697515 (P=0.47, VEGFC). Rs2910164 (MicroRNA-146a) was not present in our 
258 datasets. 
259 There are limitations in using population level e-health records, especially in differentiating 
260 age-related maculopathy from diabetic maculopathy as this information (as well as lens opacity) 
261 is not always included. However, the prevalence of age-related maculopathy in a diabetic 
262 population is typically low, indicating that this limitation may have had a lessened effect on the 
263 study (43). As visual deterioration is associated with foveal oedema, further investigation in a 
264 dataset with Optical Coherence Tomography (OCT) data characterising foveal oedema would 
265 be valuable to further investigate the findings. A better phenotyping approach of DM for the 
266 purposes of research is also required.    
267 In conclusion, we propose that the TTC39C gene is associated with DM with decreased visual 
268 acuity in a Scottish diabetic cohort using a GWAS approach. Replication studies and functional 
269 studies will help to confirm its role in DM.
270
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465
466 FIGURE CAPTIONS
467  Figure 1. Manhattan plot of the GWAS on diabetic maculopathy with decreased visual 
468 acuity (469 cases and 1,374 controls). 
469  Figure 2. Regional plot around top SNPs of the TTC39C gene area.
470  Supplementary Figure S1. Workflow of the GWAS on diabetic maculopathy with 
471 decreased visual acuity in GoDARTS.
472  Supplementary Figure S2. Q-Q plot compared expected and observed –Log10(P) 
473 values. 
Page 21 of 31






























































For Peer Review Only








Cases (mean+SD) Controls (mean+SD) P
Age , y 67.20+9.50 65.27+10.39 0.0003
Sex , n 192/277 (m/f) 630/744 (m/f) 0.068
BMI , kg/m2 31.25+4.99 31.77+5.84 0.082




HDL, mmol/L 1.37+0.36 1.33+0.34 0.018
LDL, mmol/L 2.09+0.67 2.10+0.72 0.870
HbA1c, % 8.00+1.46 7.27+1.20 <0.0001
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Table 2. SNPs of the GWAS on diabetic maculopathy with decreased visual acuity (p<1.0x10-6).
SNP: single nucleotide polymorphism 
MAF: minor allele frequency
OR: odds ratio
SE: standard error
TTC39C: tetratricopeptide repeat domain 39C
CHCHD6: coiled-coil-helix-coiled-coil-helix domain containing 6
rs11706588 and rs11718080 are included in the table for readers’ interest although the P values of these 2 SNPs did not reach GWAS 
significance. 








P value (no 
adjustment)
P value OR+SE
rs9966620 18:21680735 TTC39C A 16.33%:9.64% 7.23x10-8 4.13x10-8 1.95+0.12
rs7243626 18:21679950 TTC39C T 16.17%:9.51% 8.84x10-8 5.64x10-8 1.95+0.12
rs7240470 18:21681516 TTC39C T 16.86%:10.33% 3.20x10-7 8.05x10-7 1.80+0.12
rs11706588 3:126448513 CHCHD6 C 20.98%:13.05% 6.99x10-7 4.43x10-7 1.89+0.13
rs11718070 3:126448560 CHCHD6 T 20.98%:13.09% 8.01x10-7 5.13x10-7 1.88+0.13
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Table S1. The definition of visual acuity in GoDARTS.
Visual acuity of 6/12 means a testing eye can see at six metres while an eye with normal 
vision can see at 12 metres away.
Individuals with coding 11 to 14 were removed from study.













13 Perception of Light
14 No perception of Light
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No features ≤ 2 disc diameters from the 
centre of the fovea, enough to classify it 
as M1 or M2 from definitions below
Rescreen in 12 months
M1 (Observable) Any hard exudates within a radius of > 1 
but ≤ 2 disc diameters of the fovea centre
Rescreen in 6 months or 
refer to ophthalmology if not 
feasible
M2 (Referable) Any hard exudates or blot haemorrhages 
within a distance of ≤ 1 disc diameter of 
the fovea centre.
Refer to ophthalmology 
(these patients will not 
definitely receive immediate 




R0 (No visible 
retinopathy)
No diabetic retinopathy anywhere Rescreen in 12 month
R1 (Mild) Background Diabetic Retinopathy (BDR) – 
Mild
Presence of any one of these:
Dot haemorrhages, micro-aneurysms, 
hard exudates, cotton-wool spots, blot 
haemorrhages, flames shaped 
haemorrhages
Rescreen in 12 month
R2 (Observable 
Background)
Background Diabetic Retinopathy (BDR) – 
Observable
Four(4) or more blot haemorrhages in one 
hemi-field*
Rescreen in 6 month
R3 (Referable 
Background)
Background Diabetic Retinopathy (BDR) - 
Referable
Presence of any of the following:
 Four(4) or more blot 
haemorrhages in both superior 
and inferior hemifields
 Venous beading 
 IrMA
Refer to ophthalmology;
R4 (Proliferative) Proliferative Diabetic Retinopathy (PDR) 
Presence of active new vessels or Vitreous 
haemorrhage
Refer to ophthalmology;
Patients are likely to receive 
laser treatment or other 
intervention
R6 (Inadequate) Not adequately visualized; Retina not 
sufficiently visible for assessment
Technical failure; 
Patients for alternative 
screening examination.
IrMA, Intraretinal Microvascular Abnormality.
* The hemifields, Superior and Inferior, are demarcated by a line through the fovea centre and 
optic disc.
Source: The Scottish Diabetic Retinopathy Grading Scheme 2007 v1.0.16
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Table S3. Linkage disequilibrium among 3 SNPs.
SNP: single nucleotide polymorphism 
The values in the table indicate R-square values.
SNPID rs7243626 rs9966620 rs7240470
rs7243626 1 1 0.84
rs9966620 1 1 0.85
rs7240470 0.84 0.85 1
Page 26 of 31






























































For Peer Review Only
Table S4. The top SNPs for the GWAS on the phenotypes of DM (regardless of visual acuity, 1,240 cases) against the controls (1,374 
samples).
SNP: single nucleotide polymorphism




Chromosome SNP Positions Test NMISS OR SE L95 U95 P
1 rs3818329 192627760 ADD 2324 1.865 0.1202 1.474 2.361 2.12x10-7
3 rs12629668 147209179 ADD 2061 1.397 0.06611 1.228 1.591 4.15x10-7
6 rs117482282 165511471 ADD 2361 3.079 0.2224 1.991 4.762 4.27x10-7
13 rs1149833 50750876 ADD 2557 0.747 0.05813 0.6666 0.8372 5.23x10-7
2 rs1406230 29583321 ADD 1943 0.6923 0.07334 0.5996 0.7994 5.35x10-7
1 rs2296022 192627124 ADD 2324 1.799 0.1183 1.427 2.269 6.92x10-7
16 rs35498131 9120809 ADD 1493 0.5596 0.117 0.445 0.7038 6.94x10-7
7 rs140306040 62321151 ADD 2171 0.509 0.1365 0.3895 0.6651 7.47x10-7
7 rs73121760 62313911 ADD 2155 0.5131 0.135 0.3938 0.6685 7.71x10-7
16 rs34300094 9120719 ADD 1487 0.5589 0.1184 0.4431 0.7049 8.98x10-7
2 rs34954281 152225877 ADD 2021 0.6739 0.08045 0.5756 0.789 9.34x10-7
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Figure 1. Manhattan plot of the GWAS on diabetic maculopathy with decreased visual acuity (469 cases and 
1,374 controls). 
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Figure 2. Regional plot around top SNPs of the TTC39C gene area. 
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Figure S1. Workflow of the GWAS on diabetic maculopathy with decreased visual acuity in GoDARTS. 
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Figure S2. Q-Q plot compared expected and observed –Log10(P) values. 
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